NCT06302218

Brief Summary

Effect of iPACK block with Adductor Canal Block and ESPB on pain management, and NLR and PLR following knee arthroplasty

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 4, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 8, 2024

Completed
24 days until next milestone

Study Start

First participant enrolled

April 1, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2024

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2025

Completed
Last Updated

March 8, 2024

Status Verified

March 1, 2024

Enrollment Period

6 months

First QC Date

March 4, 2024

Last Update Submit

March 4, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Opioid consumption

    Total opiate consumption after surgery

    48 hours after surgery

Secondary Outcomes (14)

  • Time to first rescue opiate analgesia

    48 hours after procedure

  • Numerical Rating Scale [range 0:10]

    Time Frame: 4 hours after surgery

  • Numerical Rating Scale [range 0:10]

    Time Frame: 8 hours after surgery

  • Numerical Rating Scale [range 0:10]

    Time Frame: 12 hours after surgery

  • Numerical Rating Scale [range 0:10]

    Time Frame: 16 hours after surgery

  • +9 more secondary outcomes

Study Arms (3)

iPACK + ACB

ACTIVE COMPARATOR

spinal anesthesia \+ ultrasound guided iPACK (20ml 0,2% ropivacaine) with ACB (10ml 0.5% ropivacaine)

Drug: Ropivacaine 0.2% Injectable Solution

Erectro Spinae Plane Block

ACTIVE COMPARATOR

spinal anesthesia \+ ultrasound guided ESPBk - 20ml 0,2% ropivacaine

Drug: Ropivacaine 0.2% Injectable Solution

Control group

PLACEBO COMPARATOR

Only spinal anesthesia - No peripheral nerve block

Drug: control group

Interventions

iPACK block + Adductor Canal Block

Also known as: iPACK + ACB
iPACK + ACB

only spinal anesthesia

Also known as: only spinal anesthesia
Control group

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with ASA classification I-III, Aged 20-90 years, Who will be scheduled for knee arthroplasty under spinal anaesthesia.

You may not qualify if:

  • patients who have a history of bleeding diathesis,
  • take anticoagulant therapy,
  • have a History of chronic pain before surgery,
  • have Multiple trauma, cannot assess their pain (dementia),
  • have been operated on under general anaesthesia,
  • have an infection in the area and do not accept the procedure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Poznan University of Medical Sciences

Poznan, Poznań, 61-701, Poland

Location

MeSH Terms

Conditions

Osteoarthritis, Knee

Interventions

RopivacaineControl Groups

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesEpidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Łukasz Łapaj, Ph.D.

    Poznań University of Medical Sciences

    STUDY CHAIR

Central Study Contacts

Malgorzata Domagalska, Ph.D.

CONTACT

Małgorzata Domagalska, Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 4, 2024

First Posted

March 8, 2024

Study Start

April 1, 2024

Primary Completion

September 30, 2024

Study Completion

October 30, 2025

Last Updated

March 8, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
6 month after study completion
Access Criteria
from the corresponding author on the resonable request

Locations